Sala Ana Carolina Bulhões, Cunha Paulo Rowilson, Pinto Clóvis Antônio Lopes, Alves Célia Antônia Xavier de Moraes, Paiva Ingrid Barreto, Araujo Ana Paula Vieira
Universidade Estadual de Campinas (UNICAMP) - Campinas (SP), Brazil.
Faculdade de Medicina de Jundiaí (FMJ) - Jundiaí (SP), Brazil.
An Bras Dermatol. 2016 Sep-Oct;91(5 suppl 1):48-50. doi: 10.1590/abd1806-4841.20164527.
Scleromyxedema is a rare chronic cutaneous mucinosis of unknown etiology. It is characterized by papular eruption and scleroderma with microscopic evidence of mucin deposition, fibroblast proliferation, and fibrosis. Most patients with scleromyxedema have monoclonal gammopathy and systemic manifestations resulting in significant morbidity and mortality. Several types of treatment have been reported with partial or inconsistent responses. Despite showing unpredictable evolution, systemic consequences of scleromyxedema and treatment side effects may result in death. We describe a rare case of a patient with scleromyxedema without paraproteinemia with systemic involvement that evolved to death despite treatment with cyclophosphamide.
硬化性黏液水肿是一种病因不明的罕见慢性皮肤黏液水肿。其特征为丘疹性皮疹和硬皮病,并有黏液沉积、成纤维细胞增殖和纤维化的微观证据。大多数硬化性黏液水肿患者有单克隆丙种球蛋白病和全身表现,导致显著的发病率和死亡率。已有多种治疗方法的报道,但其反应部分或不一致。尽管硬化性黏液水肿的演变不可预测,但其全身后果和治疗副作用可能导致死亡。我们描述了一例罕见的硬化性黏液水肿患者,该患者无副蛋白血症但有全身受累,尽管接受了环磷酰胺治疗,病情仍发展至死亡。